Drugs

Senators Introduce Bill for Homeopathic Product Pathway

David McFarland

— 2 min read
Share

Two Republican senators have introduced legislation that would establish a distinct regulatory framework for homeopathic medicines at FDA, a move supporters say would preserve consumer access to alternative therapies while critics are likely to scrutinize provisions that exempt such products from traditional drug approval requirements.

Senators Mike Lee (R-UT) and Tommy Tuberville (R-AL) have unveiled the Homeopathic Drug Product Safety, Quality, and Transparency Act, legislation designed to create a formal FDA marketing pathway for homeopathic products and reverse regulatory actions taken by the agency in recent years. The bill would formally recognize homeopathic drug products as a category distinct from conventional pharmaceuticals and exempt them from the FDA's traditional new drug approval process.

"Americans have a right to manage their own health and choose treatments that are right for them, including homeopathic methods," Lee said in announcing the legislation. He argued that the existing regulatory framework was designed for conventional pharmaceuticals and is not well suited to evaluating homeopathic products.

Tuberville, a longtime supporter of alternative medicine, said the legislation would expand consumer access to lower-cost health options. "The reality is that too many Americans today are hooked on pharmaceuticals when they could be using homeopathic remedies," Tuberville said.

The legislation follows years of tension between homeopathic manufacturers and FDA over oversight of products marketed under homeopathic principles.

Congress first recognized homeopathic drugs under the Food, Drug, and Cosmetic Act in 1938. For decades, the FDA largely exercised enforcement discretion toward many homeopathic products sold in the U.S. That approach changed in recent years as the agency increased scrutiny of products making therapeutic claims without evidence of safety and effectiveness. FDA withdrew its long-standing compliance policy guide governing homeopathic drugs and replaced it with a risk-based enforcement framework targeting products that may present safety concerns, particularly those marketed for serious diseases, vulnerable populations, or containing potentially hazardous ingredients.

Under the proposal, homeopathic products would receive their own statutory definition and would not be considered "new drugs" under federal law.

The legislation would:

  • Create a separate FDA regulatory framework specifically for homeopathic medicines.
  • Exempt homeopathic products from the conventional premarket approval process required for prescription and over-the-counter drugs.
  • Establish safety and quality standards tailored to homeopathic products.
  • Create a Homeopathic Drug Product Advisory Committee to advise FDA on safety, labeling and regulatory issues.
  • Require FDA to issue homeopathic-specific current good manufacturing practice regulations within three years.
  • Apply federal adverse-event reporting requirements to homeopathic products.
  • Prohibit non-homeopathic products from using homeopathic terminology in labeling.
  • Clarify that homeopathic products are not biosimilars.
  • Withdraw FDA guidance issued in 2022 that industry groups argue significantly restricted the marketing of homeopathic products.

The measure would also allow labeling and dosage descriptions unique to homeopathic medicine and exempt finished homeopathic products from certain laboratory testing requirements used to verify active ingredient strength in conventional pharmaceuticals.

Read more